Table 1

Select clinical variables (asthma severity, sex, age, body mass index (BMI), pre-bronchodilator (BD) FEV1% predicted) and Th2 clinical feature associations of two molecular endotypes of corticosteroid treatment response defined by corticosteroid induced sputum cell transcriptomic change (=follow up minus baseline) in PC1 and PC3 sample coordinates, respectively, dichotomised at 0 from the 19-subject Severe Asthma Research Program study

Clinical variablesRatio // median (IQR)OR (95% CI)//Ratio // median (IQR)OR(95% CI)//
PC1 <0PC1 ≥0ranksum pPC3 <0PC3 ≥0ranksum p
# Not severe: severe asthma2:65:60.400 (0.055 to 2.933)4:63:61.333 (0.204 to 8.708)
# Female: male6:210:10.300 (0.022 to 4.060)8:28:10.500 (0.037 to 6.684)
Age (years, baseline)43.43 (41.64–50.40)45.81 (38.80–52.29)0.840450.40 (45.08–54.47)41.77 (39.22–43.18)0.0350*
BMI (baseline)32.28 (25.76–44.97)33.41 (32.32–39.98)0.544833.38 (31.32–35.42)32.66 (30.88–42.61)0.9048
Baseline blood basophil count (cells/ul)4 (3–5)69 (16–95)0.0191*5 (4–89)50 (4–74)0.9506
Baseline blood eosinophil count (cells/µl)162 (90–244)200 (148–394)0.4073244 (180–456)140 (68–188)0.0082*
Baseline blood neutrophil count (cells/µl)4025 (2921–5963)4554 (3968–5752)0.39504295 (3640–5874)4554 (3725–6057)0.8421
FeNO (ppb) baseline17.5 (7.0–37.5)29.0 (16.3–39.8)0.394232.5 (20.0–38.0)14.0 (7.0–36.5)0.3143
 Follow-up14.5 (9.0–27.5)29.0 (24.3–39.8)0.078627.0 (20.0–32.0)24.0 (8.5–36.3)0.6448
 Change−3.0 (−10.0 to 1.5)−2.0 (−6.3 to 10.5)0.4785−4.5 (−7.0 to 2.0)−1.0 (−6.0 to 4.8)0.5350
 Change, #<0 : #≥05 : 27 : 40.952 (0.144 to 6.281)7 : 35 : 41.867 (0.283 to 12.310)
Sputum eosinophil % baseline0.70 (0.30–1.85)0.20 (0.00–0.65)0.16041.20 (0.40–2.00)0.00 (0.00–0.20)0.0024*
 Follow-up0.50 (0.30–1.10)0.20 (0.00–0.43)0.11710.40 (0.20–1.00)0.20 (0.00–0.73)0.2252
 Change−0.30 (−0.55 to 0.10)−0.20 (−0.45 to 0.15)0.6132−0.45 (−1.50 to 0.20)0.00 (−0.20 to 0.40)0.0181*
 Change, #<0 : #≥06:28:31.125 (0.141 to 8.995)9:15:47.200 (0.622 to 83.342)
Pre-BD FEV1% predicted baseline70.39 (57.55–86.41)78.07 (70.71–89.94)0.395078.45 (59.77–86.87)72.33 (67.42–85.47)0.9048
 Follow-up70.67 (58.44–84.36)80.32 (59.27–87.41)0.599982.20 (57.08–87.51)75.25 (61.80–82.90)0.7802
 Change−0.17 (−2.05 to 1.89)−3.43 (−8.38 to 2.03)0.31010.51 (−2.80 to 2.25)−3.43 (−7.39 to 0.28)0.2428
 Change, #<0 : #≥04:47:40.571 (0.090 to 3.641)4:67:20.190 (0.025 to 1.432)
  • For continuous-valued clinical variables, the median (IQR) and 2-sided Wilcoxon rank-sum p value are shown. For binary-valued clinical variables (eg, asthma severity, change in pre-BD FEV1% predicted dichotomised at 0), the ratios, ORs and Fisher exact test (95% CI) are shown.

  • *indicates significance at p<0.05.